The company forecasts 10% reported revenue growth in Q2 2026, driven by strong diagnostics and water business performance.
IDEXX Laboratories projected 2026 revenue between $4.70 billion and $4.75 billion, targeting 5,500 placements of its inVue Dx systems. The company reported approximately 10% reported revenue growth and 9% organic growth in Q2 2026.
Growth was fueled by over 10% organic expansion in CAG Diagnostics recurring revenues, alongside robust global performance in Water and Livestock, Poultry, and Dairy (LPD) segments. Prior quarters showed consistent momentum in these areas, aligning with long-term strategic goals.
Management highlighted strong demand for diagnostic solutions, reinforcing confidence in the 2026 outlook. The targets reflect sustained execution across core business lines.